|Table of Contents|

Expression pattern and clinicopathological significance of PD-L1 in highly differentiated head and neck squamous cell carcinoma

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 20
Page:
3776-3780
Research Field:
Publishing date:

Info

Title:
Expression pattern and clinicopathological significance of PD-L1 in highly differentiated head and neck squamous cell carcinoma
Author(s):
YUAN Hang; WANG Shengyan; NI Hengli; WU Huiqian; LI Yangyang; CHEN Gengbiao; ZENG Hong
Department of Pathology,Sun Yat-sen Memorial Hospital of Sun Yat-sen University,Guangdong Guangzhou 510120，China.
Keywords:
head and neck; highly differentiated squamous cell carcinoma; PD-L1; tumor infiltrating lymphocytes; expression mode; diagnosis
PACS:
R739.91
DOI:
10.3969/j.issn.1672-4992.2023.20.010
Abstract:
Objective:To study the expression of programmed death receptor ligand 1 (PD-L1),the distribution of tumor infiltrating lymphocytes (TILs) and the clinicopathological characteristics in highly differentiated head and neck squamous cell carcinoma (HNSCC).Methods:The clinicopathological data of 127 patients with highly differentiated HNSCC were retrospectively analyzed.The expression of PD-L1 in cancer tissue,atypical hyperplasia tissue and normal tissues adjacent to cancer was detected by IHC,and the distribution of TILs was evaluated under HE microscope.Results:PD-L1 was highly expressed (CPS≥20,accounting for 69.3%) or lowly expressed (1≤CPS<20,accounting for 30.7%) in cancer cells or TILs of highly differentiated squamous cell carcinoma.PD-L1 had no expression (CPS<1,accounting for 29.9%) or low expression (1≤CPS<20,accounting for 69.2%) in atypical hyperplasia tissues,and high expression (CPS≥20,accounting for 0.9%) in individual cases.There was no expression in normal tissues adjacent to cancer (CPS<1,accounting for about 56%) or scattered in crypt epithelium or very few lymphocytes with low expression (CPS=1,accounting for about 22%.CPS=2,accounting for about 16%.CPS=5,accounting for about 6%),and the difference was statistically significant (P=0.000).TILs in highly differentiated squamous cell carcinoma mainly showed severe invasion (low invasion accounted for 7%,moderate invasion accounted for 38.6%,and severe invasion accounted for 54.3%).In atypical hyperplastic tissues,it mainly presented moderate infiltration (low infiltration accounted for 5.6%,moderate infiltration accounted for 52.3%,and severe infiltration accounted for 42.1%).In normal tissues adjacent to cancer,it mainly presented low degree infiltration (low degree infiltration accounted for 88%,moderate infiltration accounted for 11%,and severe infiltration accounted for 1%).The difference was statistically significant (P=0.000).The expression of PD-L1 in highly differentiated squamous cell carcinoma was positively correlated with tumor infiltrating lymphocytes (TILs)(P=0.018).In terms of expression pattern,PD-L1 was not expressed in normal tissues adjacent to cancer or a few were expressed in crypt epithelium and peripheral lymphocytes.In atypical hyperplastic tissues,it is not expressed or low expressed in the basal part of the epithelium and peripheral lymphocytes.In highly differentiated squamous cell carcinoma (4 cases of verrucous carcinoma) and early invasive carcinoma,the expression was mainly in the cancer cells at the front of invasion,and the expression site had obvious polarity.The polarity of PD-L1 expression was not obvious in extensively infiltrating squamous cell carcinoma.TILs in cancer tissue mostly gathered around the infiltrating tumor nest,and PD-L1 was highly expressed.There are few lymphocytes in normal tissues adjacent to cancer,and only a few PD-L1 positive lymphocytes can be seen.Conclusion:The high expression and correlation of PD-L1 and TILs in highly differentiated squamous cell carcinoma reflect the interaction between tumor invasion process and tumor microenvironment,and their characteristic morphological patterns may provide clues for the diagnosis of highly differentiated infiltrating carcinoma.The expression rate of PD-L1 in highly differentiated squamous cell carcinoma of the head and neck is high,higher than that in atypical proliferative tissue and significantly higher than that in normal tissues adjacent to the cancer,indicating that PD-L1 may promote the occurrence and development of HNSCC.

References:

［1］ SIEGEL R,NAISHADHAM D,JEMAL A.Cancer statistics,2013 ［J］.CA:A Cancer Journal for Clinicians,2013,63(1):11-30.
［2］ GILDENER-LEAPMAN N,FERRIS RL,BAUMAN JE.Promising systemic immunotherapies in head and neck squamous cell carcinoma［J］.Oral Oncology,2013,49(12):1089-1096.
［3］ GORDON SR,MAUTE RL,DULKEN BW,et al.PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity［J］.Nature,2017,545（7655）:495-499.
［4］ CHANG DY,SONG SH,YOU S,et al.Programmed death-1 (PD-1)-dependent functional impairment of CD4(+) T cells in recurrent genital papilloma［J］.Clinical & Experimental Medicine,2014,14(3):305-313.
［5］ DAWN E,DOLAN P,SHILPA G.PD-1 pathway inhibitors:changing the landscape of cancer immunotherapy ［J］.Cancer Control,2014,21(3):231-237.
［6］ CHEN L,FLIES DB.Molecular mechanisms of T cell co-stimulation and co-inhibition［J］.Nature Reviews Immunology,2013,13(4):227-242.
［7］ KOJIMA YA,XIAOHONG W,HONGXIA S,et al.Reproducible evaluation of tumor-infiltrating lymphocytes (TILs) using the recommendations of International TILs Working Group 2014［J］.Annals of Diagnostic Pathology,2018,35:77-79.
［8］ BOXBERG M,LEISING L,STEIGER K,et al．Composition and clinical impact of the immunologic tumor microenvironment in oral squamous cell carcinoma［J］.Journal of Immunology,2019,202(1):278-291．
［9］ DAWSON MA,KOUZARIDES T,HUNTLY BJ.Targeting epigenetic readers in cancer［J］.New England Journal of Medicine,2012,367(7):647-657.
［10］ RAIMONDI C,CARPINO G,NICOLAZZO C,et al.PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients:A molecular shield to evade immune system［J］.Oncoimmunology,2017，6(12):e1315488.
［11］陈陆俊.PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer［C］.2018年中国肿瘤标志物学术大会暨第十二届肿瘤标志物青年科学家论坛论文集,2018:158. CHEN LJ.PD-L1 expression promotes epithelial to mesenchymal transition in human esophageal cancer［C］.Proceedings of the 2018 China Cancer Markers Academic Conference and the 12th Youth Scientist Forum on Cancer Markers,2018:158.
［12］ TAUBE JM,KLEIN A,BRAHMER JR,et al.Association of PD-1,PD-1 ligands,and other features of the tumor immune microenvironment with response to anti-PD-1 therapy［J］． Clinical Cancer Research,2014,20(19):5064-5074.
［13］ ZOU W,CHEN L.Inhibitory B7-family molecules in the tumour microenvironment［J］.Nature Reviews Immunology,2008,8(6):467-477.
［14］ KIM JM,CHEN DS.Immune escape to PD-L1/PD-1 blockade:seven steps to success (or failure)［J］.Annals of Oncology,2016,27(8):1492-1504.
［15］ 田国永,鹿国英,吕志军,等.PD-1、PD-L1在口腔鳞状细胞癌中表达意义及对疾病预后价值研究［J］.实用口腔医学杂志,2021,37(06):841-844. TIAN GY,LU GY,LV ZJ,et al.Significance of PD-1 and PD-L1 expression in oral squamous cell carcinoma and prognostic value［J］.Journal of Practical Stomatology,2021,37(06):841-844.
［16］ 王海青,向婉婷,卢俊米.PD-L1在口腔鳞状细胞癌中表达的临床意义［J］.中国卫生标准管理,2023,14(06):83-87. WANG HQ,XIANG WT,LU JM.Clinical significance of PD-L1 expression in oral squamous cell carcinoma［J］.China Health Standard Management,2023,14(06):83-87.
［17］ SASADA T,SUEKANE S.Variation of tumor-infiltrating lymphocytes in human cancers:controversy on clinical significance［J］.Immunotherapy,2011,3(10):1235-1251.
［18］ ALESSANDRINI L,FRANZ L,OTTAVIANO G,et al.Prognostic role of programmed death ligand 1 (PD-L1) and the immune microenvironment in laryngeal carcinoma［J］.Oral Oncology,2020,108:104836.
［19］ PEDOEEM A,AZOULAY-ALFAGUTER I,STRAZZA M,et al.Programmed death-1 pathway in cancer and autoimmunity［J］.Clinical Immunology，2014,153(1):145-152.
［20］ BORCH TH,DONIA M,ANDERSEN MH,et al.Reorienting the immune system in the treatment of cancer by using anti-PD-1 and anti-PD-L1 antibodies［J］.Drug Discovery Today,2015,20(9):1127-1134.
［21］ ODEY C UKPO,CEDRIC V PRITCHETT,JEAN E LEWIS,et al.Human papillomavirus-associated oropharyngeal squamous cell carcinomas:primary tumor burden and survival in surgical patients［J］.Annals of Otology Rhinology and Laryngology,2009,118(5):368-373.
［22］ OSTRAND-ROSENBERG S,HORN LA,ALVAREZ JA.Novel strategies for inhibiting PD-1 pathway-mediated immune suppression while simultaneously delivering activating signals to tumor-reactive T cells［J］.Cancer Immunology Immunotherapy,2015,64(10):1287-1293.
［23］ CHEN G,HUANG AC,ZHANG W,et al.Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response［J］.Nature,2018,560(7718):382-386．
［24］ ZHANG Y,HUANG S,GONG D,et al.Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer［J］.Cellular & Molecular Immunology,2010,7(5):389-395.
［25］ UPPALURI R,DUNN GP,LEWIS JS.Focus on TILs:Prognostic significance of tumor infiltrating lymphocytes in head and neck cancers［J］.Cancer Immunology,2008,8(16):16-25.
［26］ SANCHEZ-CANTELI M,ROCIO GRANDA-DIAZ,RIO-IBISATE N D,et al.PD-L1 expression correlates with tumor-infiltrating lymphocytes and better prognosis in patients with HPV-negative head and neck squamous cell carcinomas［J］.Cancer Immunology,Immunotherapy,2020,69(10):2089-2100.
［27］ FU ZM,ZHANG DJ,GUO YY,et al.Expression of PD-L1 and CD4+ tumor-infiltrating lymphocytes predict survival in head and neck squamous cell carcinoma［J］.Molecular and Clinical Oncology,2022，16(3):59.
［28］ 王文静.PD-1/PD-L1抑制剂治疗复发/转移性头颈部鳞状细胞癌疗效及安全性的Meta分析［D］.太原：山西医科大学,2022. WANG WJ.Efficacy and safety of PD-1/PD-L1 inhibitors in the treatment of relapsed/metastatic head and neck squamous cell carcinoma:a meta-analysis［D］.Taiyuan:Shanxi Medical University,2022.

Memo

Memo:
-
Last Update: 1900-01-01